| Today's Big NewsJun 26, 2023 |
| By Nick Paul Taylor Pfizer is dropping one of its oral obesity drug candidates after seeing elevated liver enzymes in clinical trials. The setback leaves the Big Pharma’s near-term prospects resting on a candidate that is given twice as often as rival weight loss medicines in development at Eli Lilly and Novo Nordisk. |
|
|
|
| July 18-19, 2023 | Jersey City, NJ |  |
|
|
By Max Bayer Vertex could be “leading the path to insulin independence," according to analysts, after another batch of data showed that the off-the-shelf diabetes cell therapy stimulated insulin production in all evaluable patients, and that two were now insulin independent. |
By Max Bayer The U.K.'s National Cancer Research Institute is shutting down after 22 years due to a lack of funding. The non-profit opened in the early 2000's to bring together researchers nationwide with industry partners working on new therapies. |
Sponsored by Context Therapeutics Inc. In the ongoing search for new cancer treatments, companies including Context Therapeutics are developing potential therapies focused on the emerging novel oncology target Claudin 6. |
By Nick Paul Taylor Eli Lilly has laid down a marker in the race for the oral obesity market, linking its GLP-1 receptor agonist orforglipron to 14.7% weight loss at 36 weeks. The result sets a high efficacy bar for Pfizer but leaves ample room to improve on tolerability. |
Sponsored by Sciensus Are you considering expanding your orphan drug in Europe? Discover key strategies to identify, engage and support rare disease patients, ensuring treatment adherence that makes a real difference. |
By Gabrielle Masson After teasing a small data slice in May, Boehringer is now sharing more on its Zealand Pharma-partnered obesity prospect, with new data showing nearly 19% weight loss in a phase 2 trial. |
By James Waldron As if the race to get IL-17 inhibitors to market for inflammatory skin conditions wasn’t hot enough, MoonLake Immunotherapeutics has posted phase 2 data claiming to show its drug can take on all-comers in treating hidradenitis suppurativa. |
By Annalee Armstrong Takeda took an enzyme replacement therapy to regulators in January with a trail of data breadcrumbs, but now the Japanese pharma is cutting off a couple more slices from the whole loaf, showing a complete reduction in deadly blood clot attacks in patients with an ultra-rare disease. |
By Annalee Armstrong Once heralded as a potential blockbuster, FibroGen’s pamrevlumab did not live up to expectations in a phase 3 study for a chronic lung disease. It’s the second time this month that the therapy missed the mark in a clinical trial, putting the San Francisco biotech into survival mode. |
By Gabrielle Masson Invivyd and the FDA have agreed on a path toward potential emergency use authorization (EUA) of the biotech’s lead monoclonal antibody and possible follow-on candidates designed to prevent symptomatic COVID-19. |
By Helen Floersh Researchers have leveraged optogenetics, the use of light to control biological processes, to restore normal heart rhythm in rat models of afib. Their findings address some fundamental questions about whether the treatment has the potential to be translated to the clinic. |
By Fraiser Kansteiner To support production of VX-880 and a second clinical candidate for type 1 diabetes, VX-264, Vertex and Lonza are teaming up on process development and scale-up for the manufacturing of the drugmaker’s portfolio of stem cell-derived, fully differentiated insulin-producing islet cell therapies. |
By Andrea Park Abbott unveiled a new partnership with the American Diabetes Association and kicked off its previously announced WeightWatchers collaboration during the ADA’s annual scientific sessions in San Diego on Saturday. |
By Angus Liu Lundbeck CEO Deborah Dunsire is retiring on a high note in the neuroscience company’s history. After hitting the company's highest quarterly revenue in the first quarter, the five-year Lundbeck chief executive will pass the baton to UCB's neurology head. |
By Andrea Park Conformis, a nearly two-decade-old maker of 3D-printed, personalized orthopedic implants, has agreed to be acquired by a competitor in the space: restor3d, a North Carolina startup that spun out of Duke University in 2017. |
By Annie Burky Amazon's cloud unit launched the AWS Generative AI Innovation Center with a $100 million investment, its most recent bid to keep up with the AI race. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss the most expensive drugs in the U.S., plus Eli Lilly's recent acquisition, the latest company to challenge the Inflation Reduction Act, and the rest of the week's headlines. |
|
|---|
|
|
|
September 26-28, 2023 | Philadelphia, PA Hear how to drive greater sponsor-CRO-site collaboration and communication, and the latest on oversight approaches for external stakeholders. Save $400 on Registration with the Early Bird Rate! 
|
|
Whitepaper Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Autoantibody screening is promising for early cancer detection with the potential to improve the whole treatment decision tree, providing a less invasive, powerful approach. Sponsored by: Sengenics |
Whitepaper Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
Whitepaper Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Whitepaper Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
eBook See how clinical trial sponsors can build stronger strategies to address challenges across the patient enrollment funnel, starting with four necessary steps. Sponsored by: OneStudyTeam |
Whitepaper This paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| July 18-19, 2023 | Jersey City, NJ |
|
|
| |
|
